应用凝血因子Ⅺ和Ⅻ抑制剂治疗接触系统血栓的研究进展  

Research progress on the application of coagulation factor Ⅺ and Ⅻ inhibitors in the treatment of contact system thrombosis

作　　者：宣言 常思瑶 王慕宁 刘冰[1] 韩志阳[1] Xuan Yan;Chang Siyao;Wang Muning;Liu Bing;Han Zhiyang(Department of Vascular Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学第一附属医院血管外科,哈尔滨150001

出　　处：《中华血管外科杂志》2024年第3期209-214,共6页Chinese Journal of Vascular Surgery

摘　　要：接触系统血栓是指血液与身体以外的异物接触后在异物表面形成的血栓。目前针对接触系统血栓的常规预防及治疗方法增加了出血的风险。近年来, 大量试验证明应用凝血因子Ⅺ和Ⅻ抑制剂治疗血栓性疾病既安全又有效, 这为接触系统血栓的预防与治疗提供了新的思路。目前靶向抑制以凝血因子Ⅺ、凝血因子Ⅻ为主的内源性凝血途径作为一种出血风险较低的抗血栓策略已经被广泛认可, 表明凝血因子Ⅺ和Ⅻ抑制剂对于接触系统血栓的预防和治疗具有广阔的应用前景。该文就接触系统及凝血因子Ⅺ和Ⅻ抑制剂应用于接触系统血栓的研究进展和应用前景等方面做出综述。Contact system thrombosis refers to the formation of the thrombus on the surface of the foreign bodies after their contact with blood.Current routine prevention and treatment of contact system thrombosis could increase the risk of bleeding.In recent years,a large number of trials have proved that coagulation factor Ⅺ and Ⅻ inhibitors are safe and effective in the treatment of thrombotic diseases,which provides a new perspective for the prevention and treatment of contact system thrombosis.At present,targeted inhibition of the intrinsic pathway of coagulation,mainly coagulation factors Ⅺ and Ⅻ,has been widely recognized as an antithrombotic strategy with lower risk of bleeding,indicating the broad application prospects of coagulation factor Ⅺ and Ⅻ inhibitors in the prevention and treatment of contact system thrombosis.This article reviews the research progress and application prospect of contact system and coagulation factor Ⅺ and Ⅻ inhibitors in contact system thrombosis.

关 键 词：接触系统 内源性凝血途径 凝血因子Ⅺ 凝血因子Ⅻ 血栓形成 抗凝 抑制剂 出血风险 

分 类 号：R543[医药卫生—心血管疾病]